FDA Approves TEVIMBRA® for First-Line Treatment of PD-L1-Positive Gastric and Gastroesophageal Junction Cancers

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

Home
/
update
/
details

Exact Sciences Showcases Advances in Precision Oncology at 2024 SABCS

NextEdge Admin

26 Nov 2024

2 min 17 sec

Exact Sciences Corp. , a leader in cancer diagnostics, will present 10 abstracts showcasing its Precision Oncology portfolio at the 2024 San Antonio Breast Cancer Symposium® (SABCS®), December 10-13 in San Antonio, Texas.

"Exact Sciences is dedicated to enhancing breast cancer care by providing actionable insights that support informed treatment decisions and optimal patient outcomes," stated Dr. Rick Baehner, Chief Medical Officer, Precision Oncology at Exact Sciences. "For two decades, the Oncotype DX® test has been a cornerstone in personalized treatment planning. Our latest findings at SABCS reinforce its value to clinicians, researchers, and patients. Together with our OncoExTra® test and the anticipated molecular residual disease monitoring test, we are advancing innovative solutions to support patients across all stages of cancer care."

Collaborating with leading experts and institutions, Exact Sciences will share data demonstrating how the Oncotype DX test guides chemotherapy use in clinical practice and trials. New research from Japan highlights the test's role in supporting breast cancer treatment decisions and cost management. Additionally, retrospective data reveals African American women often have higher Recurrence Score® results than non-Hispanic White women, with similar survival outcomes. These findings underscore the test's potential to promote equitable breast cancer care across diverse populations while emphasizing the need for further research to address racial disparities.

Through its Precision Oncology portfolio, Exact Sciences remains committed to delivering transformative insights that advance personalized cancer care globally.